Cefaclor Capsule
NDC Package 61442-171-01

11-digit billing NDC: 61442017101

Package Information

Cefaclor capsules is cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae,staphylococci, and Streptococcus pyogenesNote: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. This formulation utilizes a capsule delivery system. Marketed by Carlsbad Technology, Inc., this product is identified by NDC 61442-171 and is authorized under FDA application ANDA065146.

Identification & Billing

NDC Package Code
61442-171-01
Package Description
100 CAPSULE in 1 BOTTLE, PLASTIC
Product Code
11-Digit Billing Format
61442017101
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Cefaclor
Non-Proprietary Name
Cefaclor
Substance Name
Cefaclor
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae,staphylococci, and Streptococcus pyogenesNote: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae,and Streptococcus pyogenesNote: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis, caused by Streptococcus pyogenesNote:Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp .,and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenesAppropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsule and other antibacterial drugs, Cefaclor Capsule should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Regulatory & Marketing

Labeler Name
Carlsbad Technology, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA065146
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-31-2008
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (61442-171). Click a package code to view its specific billing and regulatory data.

500 CAPSULE in 1 BOTTLE, PLASTIC
30 CAPSULE in 1 BOTTLE, PLASTIC

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 61442-171-01 identifies a specific commercial package of 100 capsule in 1 bottle, plastic of Cefaclor, a human prescription drug labeled by Carlsbad Technology, Inc.. This capsule is formulated for oral use and contains cefaclor as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Carlsbad Technology, Inc. on July 31, 2008. The current certification is valid through December 31, 2027.

How is this Carlsbad Technology, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 61442017101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
61442-171-01
11-Digit CMS (5-4-2)
61442-0171-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.